Four years after Sanofi shelled out $125 million for global rights to Biond Biologic | The company is handing back the tumor ...

Sanofi has shared a deeper dive into its 469 million euro ($491 million) bowel disease bet, publishing phase 2 data that ...

Sanofi successfully prices EUR 1.5 billion of bond issue Paris, March 5, 2025. Sanofi announces that it has successfully priced its offering of ...

South Africa's competition watchdog is investigating drugmakers Novo Nordisk and Sanofi over possible anti-competitive ...

Berenberg analyst Luisa Hector raised the firm’s price target on Sanofi (SNY) to EUR 120 from EUR 115 and keeps a Buy rating on the ...

The last few years have been tough for the insulin market, with recent policies and high-level pressure forcing companies to ...

We recently published a list of 10 Best Immunology Stocks To Buy Now. In this article, we are going to take a look at where ...

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be ...

The company's molecular research and drug-development platform taps what it calls nature's wisdom to drive the discovery of ...

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also significantly ...

Novo Nordisk A/S and Sanofi are facing an investigation in South Africa over concerns about potential anti-competitive practices in the human insulin pen market.